Zydus Cadila Desidustat’s better positioned to get first-to-market advantage within HIF-PHI class in India, says GlobalData Read more
Zydus to begin phase-II (a) clinical trial of oral inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome in Australia Read more
Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announces final approval from US FDA Read more